AAIC 2026 Company Presentations

Dates: July 12-15, 2026 Location: ExCeL London, United Kingdom Organizer: [Alzheimer's Association](https://www.alz.org/)[@alzorg]

Overview

Dates: July 12-15, 2026 Location: ExCeL London, United Kingdom Organizer: [Alzheimer's Association](https://www.alz.org/)[@alzorg]

Overview

The AAIC Company Presentations provide a critical platform for pharmaceutical and biotechnology companies to present their Alzheimer's disease and dementia research programs, clinical trial results, pipeline updates, and strategic directions to the global research community. As the world's largest Alzheimer's research conference, AAIC attracts presentations from major pharmaceutical companies, innovative biotechnology firms, and emerging biotech startups all seeking to showcase their therapeutic approaches["@aaic"].

This page covers the company presentations expected at AAIC 2026, their therapeutic pipelines, clinical trial programs, and the scientific data being presented. The conference serves as a crucial inflection point for companies to share data that may influence investment decisions, research collaborations, and the future direction of Alzheimer's therapeutic development.

Conference Context

Importance of AAIC for Industry

The Alzheimer's Association International Conference serves multiple critical functions for companies in the Alzheimer's therapeutics space:

AAIC 2026 Industry Track Overview

AAIC 2026 features a dedicated industry track with multiple presentation formats designed to showcase company programs comprehensively.

Company Presentation Types

Corporate Symposia

Corporate symposia are hour-long, sponsored educational sessions that provide in-depth coverage of specific therapeutic approaches or clinical programs:

• Sponsored Educational Sessions: CME-accredited presentations on disease mechanisms, therapeutic targets, or clinical approaches
• Clinical Trial Data Presentations: Detailed results from Phase II and Phase III trials
• Research Pipeline Overviews: Comprehensive reviews of company programs across discovery through clinical development
• Key Opinion Leader Presentations: External experts presenting company-sponsored research

Booth Presentations and Exhibition

The exhibition floor at AAIC provides companies with interactive spaces to engage with attendees:

• Product Information: Educational materials on approved therapies and clinical programs
• Clinical Trial Recruitment: Information about enrolling studies and eligibility criteria
• Scientific Discussions: One-on-one meetings with medical affairs and research personnel
• Technology Demonstrations: Displays of diagnostic tools, biomarker assays, and digital health solutions

Partnering Events

AAIC facilitates business development through structured partnering:

• Business Development Meetings: Pre-scheduled one-on-one meetings between company representatives and potential partners
• Collaboration Opportunities: Presentations of co-development or licensing opportunities
• Investor Sessions: Dedicated times for investment analysts to meet with company management
• Academic Collaborations: Opportunities for academic investigators to engage with company research teams

Major Pharmaceutical Partners Expected

Eisai and Biogen (Leqembi)

Leqembi (lecanemab) represents the first approved disease-modifying therapy that demonstrates meaningful clinical benefit in early Alzheimer's disease[@leqembi]. Expected presentations:

• TRAILBLAZER-ALZ 2 Trial Extensions: Long-term follow-up data from the confirmatory Phase III trial
• Real-World Evidence: Post-approval effectiveness data
• Combination Approaches: Studies combining lecanemab with other therapeutic modalities
• Subgroup Analyses: Detailed efficacy data in various patient populations
• Biomarker Correlations: tauPET and CSF biomarker data supporting mechanism

Eli Lilly (donanemab/kisunla)

Donanemab (Kisunla) received FDA approval in 2024 for treatment of early symptomatic Alzheimer's disease[@donanemab]. Expected presentations:

• TRAILBLAZER-ALZ 3 Trial: Primary prevention trial in cognitively normal individuals with elevated amyloid
• TRAILBLAZER-ALZ 2 Extension: Long-term outcomes data
• TRAILBLAZER-ALZ 4: Head-to-head comparison with Aduhelm
• Subpopulation Analyses: Efficacy in ApoE4 carriers, downs syndrome patients
• ARIA Management: Strategies for managing amyloid-related imaging abnormalities

Roche/Genentech

Roche maintains a substantial Alzheimer's pipeline with multiple programs at various stages[@roche]:

• Gantenerumab (crenezumab): Ongoing development program
• Anti-tau Programs: Multiple tau-targeting antibodies in development
• Biomarker Partnerships: Collaboration with diagnostic companies
• Combination Strategies: Approaches combining amyloid removal with other mechanisms

Johnson & Johnson

Johnson & Johnson has an evolving neuroscience portfolio with interest in Alzheimer's:

• JNJ-63733657: Anti-tau antibody program
• Neurodegeneration Pipeline: Broader CNS programs
• Diagnostic Collaborations: Partnerships in biomarker development

Merck (MSD)

Merck's neuroscience division focuses on multiple CNS conditions:

• Verubecestat Updates: BACE inhibitor program data (if presented)
• Early Pipeline: Novel approaches to Alzheimer's modification
• Biomarker Work: CSF and blood-based biomarker development

Biotechnology Companies Expected

AC Immune

AC Immune is a Swiss biotechnology company with a broad Alzheimer's pipeline[@acimmune]:

• Crenezumab: Anti-amyloid antibody (in collaboration with Roche)
• ACI-35: Phospho-tau vaccine
• ACI-24: Anti-amyloid vaccine
• SAM-760: Anti-tau antibody

Prothelia

Prothelia focuses on proteostasis in neurodegeneration:

• Synaptic Protection Programs: Approaches to preserve synaptic function
• Protein Aggregation Inhibitors: Small molecule programs

Cerevel Therapeutics

Cerevel has multiple neuroscience programs:

• CVL-231: Muscarinic agonist for cognitive enhancement
• Parkinson's Programs: Dopamine receptor modulators
• Other CNS Programs: Anxiety, depression pipelines

Vida Therapeutics

Emerging company with focus on:

• Cell Therapy Approaches: Cellular-based treatments for neurodegeneration
• Regenerative Medicine: Novel therapeutic modalities

Additional Biotechnology Companies

The AAIC exhibition typically includes numerous additional biotech companies:

• Prothelia: Synaptic protection
• Vida Therapeutics: Cell-based approaches
• Cerecin: Metabolic approaches to neurodegeneration
• NeuroPhage: Broad-spectrum aggregation inhibitors

Pipeline Summary by Therapeutic Approach

Amyloid-Targeting Therapies

| Company | Agent | Mechanism | Phase | Status |
|---------|-------|------------|-------|--------|
| Eisai/Biogen | Lecanemab | Anti-amyloid protofibril | Approved | Commercial |
| Eli Lilly | Donanemab | Anti-amyloid plaque | Approved | Commercial |
| Roche | Gantenerumab | Anti-amyloid aggregate | III | Ongoing |
| AC Immune | Crenezumab | Anti-amyloid | II | Ongoing |
| Prothelia | PR-004 | BACE inhibitor | I | Ongoing |

Tau-Targeting Therapies

| Company | Agent | Mechanism | Phase | Status |
|---------|-------|------------|-------|--------|
| Eli Lilly | Donanemab | Anti-tau | Approved | Commercial |
| Roche | Semorinemab | Anti-tau | II | Ongoing |
| AC Immune | SAM-760 | Anti-tau | II | Ongoing |
| Janssen | JNJ-63733657 | Anti-tau | I | Ongoing |

Neuroprotective and Disease-Modifying Approaches

| Company | Agent | Mechanism | Phase | Status |
|---------|-------|------------|-------|--------|
| AC Immune | ACI-35 | Phospho-tau vaccine | II | Ongoing |
| Cerevel | CVL-231 | Muscarinic M1 agonist | II | Ongoing |

Clinical Trial Results Expected

Late-Breaking Presentations

AAIC features late-breaking abstract presentations where companies and investigators present primary endpoint data from major trials:

• Extension Studies: Long-term follow-up from pivotal trials
• Biomarker Correlations: CSF, PET, and blood-based biomarker data
• Subgroup Analyses: Efficacy in various patient subpopulations

Publication Implications

Data presented at AAIC often leads to subsequent peer-reviewed publications, with company-sponsored trials frequently published in high-impact journals following conference presentation.

Scientific Highlights to Expect

Biomarker Discussions

• Amyloid PET Standardization: Centiloid scale adoption
• Tau PET Interpretation: Regional tau and clinical correlation
• Fluid Biomarkers: p-tau217, p-tau181, NFL in clinical practice
• Combination Biomarkers: Multi-marker panels for patient selection

Clinical Outcome Measures

• ADAS-Cob: Alzheimer's Disease Assessment Scale
• Clinical Dementia Rating: CDR scores in trials
• Cognitive Function Batteries: Novel endpoints being validated
• Real-World Outcomes: Functional measures in clinical practice

Regulatory Considerations

• FDA Guidance: Updates on regulatory expectations
• Accelerated Approval: Lessons from amyloid antibodies
• Clinical Endpoints: FDA perspectives on approvable endpoints

Industry Networking Opportunities

Company-Sponsored Events

• Reception Hosts: Company-sponsored networking receptions
• Investor Days: Formal investor presentations
• Investigator Meetings: Principal investigator gatherings

Academic-Industry Collaboration

• Research Grants: Industry funding for academic research
• Data Sharing Initiatives: Consortium participation
• Biomarker Development: Collaborative assay development

Future Directions in Alzheimer's Therapeutics

Emerging Modalities

• Gene Therapy: Approaches to deliver therapeutic genes
• Cell Therapy: Cellular replacement strategies
• Small Molecule Modulators: Novel mechanisms beyond amyloid
• Combination Approaches: Multi-target therapeutic strategies

Precision Medicine

• Biomarker-Driven Selection: Patient selection based on biomarkers
• Personalized Approaches: Tailored therapeutic interventions
• Prevention Trials: Preclinical disease modification

Related NeuroWiki Content

Alzheimer's Disease Treatments

• [Leqembi (lecanemab)](/therapeutics/leqembi)
• [Donanemab](/therapeutics/donanemab)
• [Aduhelm](/therapeutics/aduhelm)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

Related Conferences

• [AAIC 2026 Conference](/events/aaic-2026)
• [AAIC 2026 Plenary Sessions](/events/aaic-2026-plenary-sessions)
• [AAIC 2026 Scientific Sessions](/events/aaic-2026-scientific-sessions)
• [AAIC 2026 Clinical Trials](/events/aaic-2026-clinical-trials)
• [Conference Index](/events/conference-index)

Therapeutic Mechanisms

• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Tau Pathology in AD](/mechanisms/tau-pathology-ad)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation)

External Resources

• [AAIC 2026 Official Website](https://aaic.alz.org)
• [AAIC 2026 Program](https://aaic.alz.org/program)[@aaic]
• [Alzheimer's Association](https://www.alz.org/)[@alzorg]
• [Leqembi FDA Approval](https://www.fda.gov/drugs/news-events-human-drug-alerts/fda-approves-new-treatment-alzheimers-disease)[@leqembi]
• [Donanemab FDA Approval](https://www.fda.gov/drugs/fda-approves-donanemab-azilect-alzheimers-disease)[@donanemab]

References